✦ LIBER ✦

Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

✍ Scribed by Davidson, J. A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incretin-based treatment of type 2 diabe

✍ Carolyn F. Deacon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

The incretin system: glucagon-like pepti

✍ Daniel J Drucker; Michael A Nauck 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 320 KB

Incretin-based Therapies (Glucagon-like

✍ Amir Hanna; Vincent Woo; Jean-François Yale; Elaine M. Cooke 📂 Article 📅 2012 🏛 Canadian Diabetes Association 🌐 English ⚖ 208 KB

Novel therapeutics for type 2 diabetes:

✍ E.J. Verspohl 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 913 KB

Reshaping Diabetes Care: The Fundamental

✍ Umpierrez, Guillermo; Meneghini, Luigi 📂 Article 📅 2013 🏛 American Association of Clinical Endocrinologists 🌐 English ⚖ 510 KB

Glycaemic efficacy of glucagon-like pept

✍ C. F. Deacon; E. Mannucci; B. Ahrén 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB